Table 1.
Baseline clinicopathological parameters of included patients
| Paired (N = 83) | Metastatic (N = 80) | P value | |
|---|---|---|---|
| Age, n (%) | 0.546 | ||
| < 70 | 76 (91.6) | 71 (88.8) | |
| ≥ 70 | 7 (8.4) | 9 (11.2) | |
| Gender, n (%) | 0.873 | ||
| Male | 54 (65.1) | 53 (66.3) | |
| Female | 29 (34.9) | 27 (33.7) | |
| ISUP, n (%) | 0.066 | ||
| < 4 | 49 (67.1) | 58 (80.6) | |
| ≥ 4 | 24 (32.9) | 14 (19.4) | |
| Histological Type, n (%) | 0.032 | ||
| ccRCC | 59 (71.1) | 68 (61.3) | |
| Non-ccRCC | 24 (28.9) | 12 (38.7) | |
| Pathology, n (%) | |||
| Sarcomatoid | 6 (19.4) | 2 (28.6) | 0.509 |
| Necrosis | 25 (80.6) | 5 (71.4) | 0.491 |
| Nephrectomy, n (%) | 0.001 | ||
| Yes | 80 (96.4) | 57 (77.0) | |
| No | 3 (3.6) | 17 (23.0) | |
| ECOG, n (%) | 0.801 | ||
| 0–1 | 53 (70.7) | 59 (76.6) | |
| ≥ 2 | 22 (29.3) | 18 (23.4) | |
| IMDC, n (%) | 0.293 | ||
| Low | 14 (18.3) | 19 (28.4) | |
| Intermediate | 43 (57.3) | 37 (55.2) | |
| High | 18 (24.0) | 11 (16.4) | |
| T stage, n (%) | 0.587 | ||
| < 2b | 46 (59.7) | 12 (66.7) | |
| ≥ 2b | 31 (40.3) | 6 (33.3) | |
| Metastasis, n (%) | |||
| Lung | 6 (8.1) | 17 (28.8) | 0.010 |
| Brain | 7 (9.5) | 12 (20.3) | 0.192 |
| Liver | 1 (1.4) | 2 (3.4) | 0.539 |
| Bone | 18 (24.3) | 22 (37.3) | 0.389 |
| Lymph node | 42 (56.8) | 6 (10.2) | 0.001 |
| Treatment, n (%) | |||
| Cytokine | 14 (16.9) | 8 (10.0) | 0.345 |
| Target therapy | 34 (41.0) | 30 (37.5) | 0.882 |
| Radiotherapy | 7 (8.4) | 7 (8.8) | 0.673 |
| Chemotherapy | 3 (3.6) | 5 (6.2) | 0.360 |
| Unknown | 25 (30.1) | 30 (37.5) | |